BC is a heterogeneous malignancy that is traditionally classified by the expression of specific hormone receptors (i.e., estrogen receptor [ER] and progesterone receptor [PR]), as well as the overexpression of human epidermal growth factor receptor 2 (HER2) [2–4]. This evidence concerns the gene ESR1 and breast cancer.